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Abstract: Renal transplantation represents the most favorable treatment for patients with 
advanced renal failure and it is followed, in most cases, by a significant enhancement  
in patients’ quality of life. Significant improvements in one-year renal allograft and 
patients’ survival rates have been achieved over the last 10 years primarily as a result of 
newer immunosuppressive regimens. Despite these notable achievements in the short-term 
outcome, long-term graft function and survival rates remain less than optimal. Death with  
a functioning graft and chronic allograft dysfunction result in an annual rate of 3%–5%.  
In this context, drug toxicity and long-term chronic adverse effects of immunosuppressive 
medications have a pivotal role. Unfortunately, at the moment, except for the evaluation  
of trough drug levels, no clinically useful tools are available to correctly manage 
immunosuppressive therapy. The proper use of these drugs could potentiate therapeutic 
effects minimizing adverse drug reactions. For this purpose, in the future, “omics” 
techniques could represent powerful tools that may be employed in clinical practice  
to routinely aid the personalization of drug treatment according to each patient’s genetic 
makeup. However, it is unquestionable that additional studies and technological advances 
are needed to standardize and simplify these methodologies. 
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1. Ensuring Long-Term Graft Survival in Renal Transplantation: A Matter of  
Adequate Immunosuppression 
Renal transplantation is the gold standard therapy for patients affected by end stage renal disease,  
a clinical condition characterized by severe biological/biochemical alterations that require renal 
replacement therapy to ensure patients’ survival, and it is followed, in most cases, by a significant 
improvement of patients’ quality of life, reduction of medical expenses and prolongation of life [1–3]. 
In fact, immediately after transplantation, patients experience rapid and significant changes of their 
clinical conditions and undergo considerable physiological modifications [4,5]. 
However, sometimes, transplanted subjects may undergo important clinical complications  
(e.g., infections, malignancies and cardiovascular diseases) most of the time drug-induced. In fact,  
the actual employed immunosuppressant medications, although valuable against short-time graft 
complications (including acute renal rejection), are still less effective to ensure long-term graft 
survival. As reported, death with a functioning graft and chronic allograft dysfunction (CAD) are still 
elevated, with an annual rate of 3%–5% [6]. 
CAD is defined as a functional and morphological deterioration of a renal allograft at least  
3–6 months after transplantation due to non-immunological (mainly calcineurin inhibitors-induced 
nephrotoxicity) and immunological (e.g., chronic antibody mediated rejection-CAMR) factors [7]. 
During this process, any anatomical component of the allograft kidney may undergo 
fibrosing/sclerosing changes: (a) glomeruli may increase progressively in the matrix and/or may 
develop segmental or global sclerosis; (b) arterial intima may be affected by fibrosis, and accumulation 
of hyaline material in small arteries and arterioles; (c) peritubular capillaries may develop multilayered 
basal lamina, and there may be thickening of glomerular capillary walls with reduplication of the 
basement membrane and mesangial interposition and (d) the downstream interstitial matrix could 
increase resulting in interstitial fibrosis and collagen scar accompanied by progressive tubular atrophy [8]. 
In addition, substantial evidence implicates major histocompatibility complex alloantibodies as  
a cause of late graft loss [9]. Capillary deposition of C4d, a split product of the classical pathway of 
complement activation, is an established marker of antibody-mediated allograft rejection early after 
transplantation [10–14]. In acute rejection, this complement split-product has been shown to be closely 
associated with the presence of alloantibodies. C4d was also identified in renal allograft biopsies with 
morphologic signs of chronic rejection [13,15]. 
It seems clear that, in this context, a correct administration of immunosuppressive drugs, 
minimizing/avoiding the onset and development of all above-mentioned graft damages, and  
maximizing its ability to control rejection, may result in a significant improvement of the graft and 
patients’ survival. 
However, at the moment, the methodologies to adjust the dosage of these drugs with a narrow 
therapeutic index (such as calcineurin inhibitors, mammalian target of rapamycin inhibitors and 
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antiproliferative medications) generally provide inadequate, non-reproducible and poor predictive of 
efficacy/toxicity before drug administration results [16]. 
Additionally, as largely described, inherited differences in drug metabolism and disposition and 
genetic variability in therapeutic targets (e.g., receptors) need to be taken into account because of their 
role in modulating drug effects and toxicities [17–19] (Figure 1). 
Liver: drugs detoxification
CYP3A4, CYP3A5  TAC, mTOR-I
UGT1A9MMF
Systemic: drugs metabolic 
pathways
IMPDH MMF/MPA 
TPMT  AZA
Donor kidney: drugs nephrotoxicity
ABCB1 CsA
Intestine: drugs uptake
ABCB1mTOR-I  
Figure 1. Tissue localization of major polymorphic enzymes involved in metabolism and 
disposition of immunosuppressive drugs. TAC: Tacrolimus; mTOR-I: mammalian target of 
rapamycin (mTOR) inhibitors; CsA: Cyclosporin A; MPA: Micophenolic acid; MMF: 
Mycophenolate mofetil; AZA: Azathioprine. 
For these reasons researchers and clinicians worldwide are working together to identify minimally 
invasive biomarkers useful to personalize therapy based on patients’ genetic/genomic characteristics, 
to select valuable molecular tools for drug monitoring and to recognize biomarkers able to early 
identify patients at high risk to develop chronic graft damage in which an early therapeutic change may 
alter transplant outcomes. 
It is expected that, during the coming years, the use of “omics” techniques may have a critical 
impact in the transplant field facilitating the achievement of these crucial objectives. 
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2. Understanding the Genetic Influence in Drug Response: A First Step to Personalize 
Immunosuppressive Treatment in Renal Transplantation 
The current therapy of renal transplantation employs several immunosuppressive agents  
(Figure 2 and Table 1), most of the time combined, commonly classified according to their mechanism  
of actionsCalcineurin inhibitors (Cyclosporine A, Tacrolimus); Inhibitors of purine synthesis 
(Mycophenolate mofetil/Mycophenolic Acid and Azathioprin); Mammalian target of rapamycin 
inhibitors (Sirolimus and Everolimus). 
These drugs are frequently co-administered with glucocorticoids (Methylpredinosolone, 
Prednisolone) and, during induction therapy, with monoclonal or polyclonal antibodies (e.g., 
Basiliximab, Tymogobulin) [20]. 
 
Figure 2. Mechanisms of action and targets of immunosuppressive drugs used in renal 
transplantation. MPA: Micophenolic acid; MMF: Mycophenolate mofetil. 
2.1. Calcineurin Inhibitors (CNIs) 
CNIs, cyclosporin A (CsA) and tacrolimus (TAC), currently employed as the backbone of most 
immunosuppressive regimens in renal transplantation, have similar mechanisms of action. 
Briefly, CsA acts by complexing with cyclophilin and, after the inhibition of the activity of 
phosphatase calcineurin, prevents the translocation of nuclear factors of activated T cells (NFAT)  
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into the nucleus with a subsequent inhibition of the transcription of several genes encoding for 
cytokines and other immune mediators, particularly IL-2. TAC acts through immunophilin FK binding 
protein-12 (FKBP12) to produce downstream inhibition of the same pathway. Inhibition of calcineurin 
by these agents blocks T-cell activation and, consequently, immune response propagation [21]. 
Although both drugs share a similar mechanism of action, and the same drug transporter and 
metabolizing enzymes are involved, important differences exist between them (Table 1). 
TAC is mainly metabolized by two enzymes of the cytochrome P450 family, CYP3A5 and  
CYP3A4 [22,23]. Therefore disposition and dose to blood concentration ratio of TAC seem to be 
influenced by the polymorphic genetic variants of these two genes. 
The main determinant is a single-nucleotide polymorphism (SNP) in intron 3 of CYP3A5 (6986A>G; 
SNP rs776746), also known as CYP3A5*3. CYP3A5*3 allele is a splice variant with a premature stop 
codon and encodes an enzyme with a reduced activity. Patients homozygous for this variant require  
a dose of TAC approximately 50% lower to reach the blood target concentration compared with 
carriers of the CYP3A5*1 allele (wild-type) [24–27]. This condition has a major clinical impact 
considering that around 5%–15% of white individuals are expected to express CYP3A5*1, whereas 
approximately 30% of Asians, and 70% of individuals of African descent express this variant [28]. 
Therefore, a correct genotyping for CYP3A5, while on the waiting list for transplantation, could  
be useful to optimize TAC dosage in the post-transplant period [29,30]. 
Then, the CYP3A4 polymorphisms may also affect TAC pharmacokinetics. The CYP3A4*22 
(rs35599367; c.522-191C>T in intron 6) SNP has been linked to reduced CYP3A4 mRNA expression 
and lower in vitro CYP3A4 enzyme activity [31]. In renal transplant recipients, the CYP3A4*22  
T-variant allele was associated with a reduced TAC dose requirement, independent of CYP3A5 
genotype [32]. 
Additionally, the CYP3A4*1B SNP involves an A to G transition on promoter region of CYP3A4 
(−392A>G) and has been linked to an increased CYP3A4 activity. Tavira et al. [33] report that, at one 
year post-transplant, the patients who were CYP3A5*3/*3 + CYP3A4*1B carriers had TAC C0 values 
in the target range, whereas those carrying the CYP3A5*3/*3 + CYP3A4*1/*1 alleles (approximately 
6%) were out of this range. 
Most of the CYP3A4 variants found in the coding region have an allele frequency <1%.  
An exception was CYP3A4*2, a SNP in exon 7 (15713T>C) that results in a Ser222Pro change with  
a frequency of 5% among the Caucasians but its effect on TAC bioavailability has not been 
established. This allele was linked to a lower clearance of the CYP3A4 substrate nifedipine, and 
carriers of this allele can thus be classified as “slow metabolizers” [34,35]. 
ABCB1 (or MDR-1) is the gene codifying for P-glycoprotein, a transmembrane efflux pump moving 
drugs from the intracellular to the extracellular domain thereby influencing the absorption, cellular 
metabolism, and toxicity of pharmacological agents [36]. The most common and extensively studied 
ABCB1 SNPs include a C to T transition at position 3435 within exon 26 (rs1045642), a C to T 
transition at position 1236 within exon 12 (rs1128503) and a G to T or A transition at position 2677 
within exon 21 (rs2032582) of the ABCB1 gene [37]. 
Influence of ABCB1 SNPs on TAC pharmacokinetics remains uncertain because several studies 
obtained conflicting results [29,38–43]. 
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CsA is mainly metabolized by the CYP3A4 enzyme but neither polymorphisms in this gene, nor in 
the ABCB1 gene, seem to have a strong effect on the dose to blood concentration ratio of CsA [44–46]. 
However, measurement of ABCB1 activity in PBMC of renal transplant recipients revealed  
that TT carrier patients on C3435T, G2677T, and C1236T SNPs showed lower ABCB1 activity than 
non-carriers [47]. A lower ABCB1 activity, particularly due to the 3435T variant allele causes  
an increased intracellular concentration of CsA thereby exposing the patients to a higher risk of  
drug-related adverse effects [48]. Other authors reported an association between reduction of 
intracellular CsA T-lymphocyte concentration and rejection episodes [49]. 
Interestingly, several studies have reported an association between ABCB1 polymorphisms in 
donors and long-term graft survival. In particular, the TT variant allele at the 3435 position in ABCB1 
either in the donor or in the recipient were associated with decreased renal allograft function or graft 
loss in the long-term post-transplant [50–56]. In addition it has been reported that the ABCB1 1199G>A 
polymorphism is associated with better long-term renal function [57]. 
However, although most of the tacrolimus-related pharmacogentic studies are encouraging, the only 
published randomized controlled-study using this approach (TACTIC study) reported that adaptation 
of TAC dose according to the CYP3A5 genotype in renal transplant recipients did not reduce the 
incidence of delayed graft function, the number of post-transplant dialysis sessions per patient or the 
number of acute rejection episodes compared to the standard dose regimen [58]. 
2.2. Mycophenolate Mofetil (MMF) 
MMF is a prodrug that is rapidly hydrolyzed to the active metabolite, mycophenolic acid  
(MPA), and acts by blocking nucleic acid synthesis through potent, selective, noncompetitive 
inhibition of inosine monophosphate dehydrogenase (IMPDH) a key enzyme of the de novo synthesis of 
guanosine nucleotides. 
By inhibiting the de novo pathway for purine synthesis, a biochemical machinery utilized by 
lymphocytes, this agent is able to dramatically and selectively reduce B and T lymphocyte 
proliferation. In fact, other rapidly dividing cells are capable of recycling purine nucleotides through 
the “salvage” pathway, which is not inhibited by MPA [59]. 
MPA is metabolized to inactive 7-O-mycophenolic acid MPA glucuronide (MPAG) via hepatic  
UDP-glucuronosyltransferase (UGT), particularly UGT1A9, and is then deglucuronidated in the 
gastrointestinal tract and reconverted into MPA in the gut lumen where it is then reabsorbed through 
enterohepatic recirculation [59–61]. The acyl glucuronide (AcMPAG), is another MPA metabolite 
with immunosuppressive activity, formed by UGT2B7 [61]. MPA is extensively bound (97%–98%)  
to serum albumin. Accumulation of MPAG in patients with severe renal dysfunction has been shown 
to compete with free MPA for binding to albumin, leading to an increase in the serum concentration of 
free MPA [44,62]. 
There are currently no definitive pharmacogenetic associations that have been identified for MPA, 
although some potential associations between specific polymorphisms and pharmacokinetic and 
incidence of adverse effects appear promising (Table 1). 
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In particular, several reports have shown that two SNPs in the promoter region of the UGT1A9 
gene, −2152C>T and −275T>A are associated with an enhanced glucuronidation of MPA to MPAG [63] 
and significantly reduced MPA levels in the early phase after renal transplantation [64,65]. 
Van Schaik et al. [66] confirmed that the UGT1A9 −275T>A and/or −2152C>T polymorphisms 
were associated with an average 20% lower MPA exposure (consistent with an higher enzymatic 
activity) and with a significantly increased risk of acute rejection in fixed-dose MMF-treated patients 
who received TAC; the effect of these polymorphisms on MPA level were confirmed by other 
researchers [63,64,67,68]. 
The less frequent UGT1A9*3 SNP, present in less than 5% of the white population, was associated 
with a higher MPA exposure, in accordance with a reduction of in vitro enzymatic activity [63–65]. 
Although polymorphisms in other genes have also been reported to be associated with MPA 
pharmacokinetics, it is well accepted that SNPs in UGT1A9 have the strongest influence [64,69,70]. 
Furthermore, polymorphisms in genes associated with drug transport (including ABCB1 and 
SLCO1B1) or drug metabolism (UGT1A8 and UGT2B7) have been linked to adverse events, especially 
diarrhoea and haematological adverse effects, in patients treated with MMF [71–76]. However, none 
of these studies have been translated into clinical practice. 
Additionally a part of the pharmacogenetics of MMF has been focused on IMPDH, a rate-limiting 
enzyme in the de novo pathway of guanosine nucleotide synthesis. IMPDH exists in two isoforms 
IMPDH-1 and IMPDH-2 derived from different genes and several SNPs have been reported [77–80]. 
An association has been shown between high IMPDH activity prior to transplant and acute 
transplant rejection [81], suggesting that patients with high activity may theoretically need more MMF 
for equivalent immunosuppression. Patients with low IMPDH activity require a lower MMF dosage to 
obtain the same immunosuppressive effect [81]. 
Wang et al. [80,82] reported that the rs2278293 and rs2278294 SNPs within intron 7 of IMPDH-1 
are significantly associated with the incidence of biopsy-proven acute rejection one year after renal 
transplantation. Although the mechanism of this association has not been determined, the authors 
suggest the possible linkage to other SNPs [80]. 
IMPDH-2 is more conserved than IMPDH-1 and an association was found between 3757T>C 
polymorphism and an increased enzymatic activity in MMF-treated renal transplant patients [83]. 
Patients with at least one variant IMPDH-2 3757C allele had a mean IMPDH activity 48% higher 
compared with IMPDH-2 3757TT wild-type patients although there is conflicting data evaluating the 
impact of this variant on acute rejection risk [84]. 
Shah et al. [85] in 2012, analyzing 1000 renal transplant recipients, found no association between 
IMPDH variants and renal allograft rejection and graft survival. 
Overall, there is currently not enough data to suggest that routine pharmacogenomic testing would 
enhance patient outcomes in relation to mycophenolate safety and efficacy. 
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2.3. Mammalian Target of Rapamycin Inhibitors (mTOR-Is) 
The mTOR-Is, sirolimus and everolimus, represent a class of proliferation signal inhibitors used in 
renal transplantation with a wide spectrum of activities, including suppression of T-cell proliferation 
and reduction of tumor growth. 
The main mechanism of action of these drugs is the inhibition of the mammalian target of 
rapamycin (mTOR). mTOR is a regulatory protein kinase involved in lymphocyte proliferation, 
developmental processes such as neurologic and muscle generation, and tumor cell growth. Sirolimus 
(SRL; Rapamune, Wyeth Pharmaceuticals, New York, NY, USA) was the first mTOR-I approved for 
use in renal transplant recipients and binds to FKBP-12. Everolimus (EVR), marketed as Certican, was 
recently approved and is structurally similar to SLR but with the addition of an extra hydroxyethyl 
group at position 40. Although the pharmacokinetic characteristics are similar between the two mTOR 
inhibitors, EVR was developed in an attempt to improve the pharmacokinetic characteristics of SRL 
and oral bioavailability with a shorter elimination half-life that necessitates twice-daily dosing versus 
once-daily dosing [86]. 
EVR and SRL are metabolized primarily by the CYP3A family of enzymes [87,88] and ABCB1. 
Several studies have investigated the influence of SNPs in CYP3A4 and CYP3A5 genes on the dose 
requirement and clearance of the immunosuppressant (Table 1). 
In particular, lower SRL concentration/dose ratio was observed in the CYP3A5*1 (CYP3A5 
expresser) carriers than in the CYP3A5*3/*3 carriers (non-expressers), suggesting that CYP3A5  
non-expressers require a lower SRL daily dose to achieve adequate blood concentration. Patients with 
CYP3A5*1/*1 are more likely to have a higher liver metabolism and require a higher daily dose to 
achieve adequate blood SRL levels [89,90]. 
Moreover, patients carrying the CYP3A4*1B (−392A>G) allele, being associated with a higher 
enzymatic activity, require higher SRL doses to achieve adequate blood concentrations [89]. 
These results were found only for SRL, but not in all studies, and only in patients not treated with  
CNIs [91–93]. 
Recently, new polymorphisms have been discovered: CYP3A4*22, in intron 6 of CYP3A4  
gene, POR*28 (P450 (cytochrome) oxidoreductase) (rs1057868-C>T), and PPARA (peroxisome 
proliferator-activated receptor alpha) (rs4253728-G>A), but they do not have any impact on the 
pharmacokinetics of SRL or the occurrence of SRL adverse events in kidney transplant recipients [94]. 
Moreover, Sam et al. [95] reported that the mean SRL concentration:dose ratio was 48% higher in 
patients with the ABCB1 3435CT/TT genotype than in those with the 3435CC genotype, and was 24% 
higher in IL-10 −1082GG homozygotes than in those with −1082AG/AA, consistent with enhanced 
IL-10 expression leading to lowered CYP3A activity and reduced SRL metabolism in patients with 
this genotype [96,97]. In another study the same authors suggest an association between the same 
SNPs and higher triglyceride levels after SRL treatment [98]. 
Similarly to CNIs, mTOR inhibitors carry several adverse effects (including hypertriglyceridemia, 
hyperlipidemia, edema, pulmonary fibrosis, anemia) and they may potentiate nephrotoxicity with 
increased urinary protein excretion [99,100]. 
  
Int. J. Mol. Sci. 2015, 16 4289 
 
 
2.4. Azathioprine (AZA) 
AZA is one of the older immunosuppressive medications used in nephrology and in the treatment  
of inflammatory bowel disease and several autoimmune diseases. It is converted mainly in the liver 
into 6-mercaptopurine (6-MP), possibly as a result of a glutathione-S-transferase (GST) catalyzed  
reaction [101]. Conversion of 6-MP by the enzyme hypoxanthine guanine phosphoribosyltransferase 
leads to the formation of 6-thioguanine-nucleotides (6-TGN), that, when incorporated into DNA, are 
directly cytotoxic and also suppress de novo purine synthesis [102]. The thiopurine methyl-transferase 
(TPMT) pathway leads to the methylation of 6-MP forming 6-methylmercapotpurine, an inactive  
form of AZA [103,104]. Thus, the metabolism of thiopurines by TPMT shunts the drug down the 
methylation pathway and away from the active pathway [105]. 
This enzyme is encoded by the TPMT gene and its activity exhibits genetic polymorphism: 
approximately 90% of individuals inherit high activity, 10% have intermediate activity because of 
heterozygosity, and 0.3% have low or no detectable enzyme activity because they inherit two 
nonfunctional TPMT alleles [106]. 
To date, 20 variant alleles (TPMT*2-*18) have been identified, which are associated with  
decreased activity compared with the TPMT*1 wild-type allele [107]. Three alleles—TPMT*2, *3A, 
and *3C—account for up to 95% of intermediate or low enzyme activity cases [108]. The pattern and 
frequency of mutant TPMT alleles is different among various ethnic populations [109]. The TPMT*3A 
allele contains two point mutations: G460A in exon 7 and A719G in exon 10 that lead to Ala154Thr 
and Tyr240Cys amino acid substitutions, TPMT*3C has only a single A719G transversion, and 
TPMT*2 contains a G238C transversion, producing Ala80Pro substitution [110,111]. Other identified 
variant alleles are very rare (*3B) or were found only in single individuals (*4–*18) [112]. 
The impaired or absent ability to metabolize AZA through TPMT leads to high blood levels of TGN 
and an increased risk of developing severe and potentially life-threatening myelotoxicity when no dose 
reductions are performed [113–118] (Table 1). Dervieux et al. [119], measuring the TPMT activity in 
red blood cells of pediatric patients after renal transplantation, demonstrated that elevated TPMT 
activity was associated with an increased risk of acute rejection. 
Moreover Thervet et al. observed that TPMT induction (caused by the rise of the concentration of 
its substrate, 6-MP) is associated with a lower incidence of clinical acute rejection [120]. 
Genotyping for TPMT polymorphisms, before initiation of AZA therapy is one of the few examples 
of a pharmacogenetic test that has made the transition from research into clinical practice, especially 
for autoimmune disease [121]. This testing improves safety by avoiding full-dose treatment in patients 
with a (partial) enzyme deficiency [118]. 
Owing to the association between homozygous and heterozygous genotypes and low to moderate 
TMPT activity leading to increased bone marrow suppression, the Clinical Pharmacogenetics 
Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine 
Dosing endorse genotyping prior to initiating AZA therapy to inform dosing or for selection of 
alternate therapy [122]. 
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Table 1. Gene polymorphisms and their effects. 
Drug Gene Polymorphism Biological Effect Clinical Effect References 
Tacrolimus 
(TAC) 
CYP3A5 
CYP3A5*3 
(6986A>G)  
Reduction of 
CYP3A5 activity 
Reduced TAC dose 
requirement 
[24–27] 
CYP3A4 
CYP3A4*22 
Reduction of 
CYP3A4 activity 
Reduced TAC dose 
requirement 
[31,32] 
CYP3A4*1B 
(392A>G) 
Increment of 
CYP3A4 activity 
Increased TAC dose 
requirement  
[33] 
ABCB1 
3435C>T 
Altered ABCB1 
activity 
Influence on TAC dose 
requirement is uncertain 
[29,38–43] 
1236C>T [38–43] 
2677G>T/A [38–43] 
Ciclosporin 
(CsA) 
ABCB1 3435C>T 
Reduction of 
ABCB1 activity 
Increased CsA intracellular 
concentration; TT variant is 
associated with CsA 
nephrotoxicity and  
long-term graft survival   
[48,50–56] 
Mycophenolate 
mofetil/Mycop
henolic acid 
(MMF/MPA) 
UGT1A9 
2152C>T275T>A 
Increment of 
UGT1A9 activity
Increased risk of  
acute rejection 
[66] 
UGT1A9*3 
Reduction of 
UGT1A9 activity
Influence on MPA 
pharmacokinetics 
[64,65] 
IMPDH-1 
rs2278293 Most likely 
associated with 
an increment of 
IMPDH activity 
Probably associated with 
the incidence of  
biopsy-proven  
acute rejection 
[80,82] 
rs2278294 
IMPDH-2 3757T>C 
Increment of 
IMPDH activity 
No association with 
rejection risk 
[84] 
Sirolimus 
(SRL) 
CYP3A5 CYP3A5*3 
Reduction of 
CYP3A5 activity 
Reduced SRL dose 
requirement 
[89,90] 
CYP3A4 
CYP3A4*1B 
(392A>G)  
Increment of 
CYP3A4 activity 
Increased SRL dose 
requirement 
[89] 
ABCB1 3435C>T 
Reduction of 
ABCB1 activity 
Patients 3435CT/TT have 
increased SRL 
concenttration:dose ratio 
[95] 
Everolimus 
(EVR) 
CYP3A5 CYP3A5*3 
Reduction of 
CYP3A5 activity 
No impact on EVR 
pharmacokinetics 
[92] 
Azathioprine 
(AZA) 
TPMT 
TPMT*2 
Reduction of 
TPMT activity 
High risk of myelotoxicity [113–118] 
TPMT*3A 
TPMT*3B 
TPMT*3C 
3. Pharmacogenomics: Looking to the Polygenetic Influence in the Response to Drug Therapy 
The completion of the Human Genome Project [123,124] and the development of innovative  
high-throughput screening technologies (e.g., genome wide scans, haplotype analysis and candidate 
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gene approaches) has led to the development of pharmacogenomics, a new science that, screening the 
entire genome, is able to recognize determinants of drug responses or toxicities. 
The Food and Drug Administration (FDA) has defined pharmacogenomics as “the study of 
variations of DNA and RNA characteristics as related to drug response”, whereas “pharmacogenetics”  
is “the study of variations in DNA sequence as related to drug response” [125]. More specifically, 
pharmacogenomics evaluates molecular determinants at the genome-, transcriptome-, and proteome-wide 
levels, whereas pharmacogenetics involves limited and specific genetic markers [126,127]. 
The use of pharmacogenetics/pharmacogenomics in clinical practice to personalize the dosage of  
a specific medication avoiding/minimizing its toxicity and enhancing its therapeutic effects, is referred 
as “personalized medicine”. 
Pharmacogenomic data may be integrated in the labeling of a product determining a clear 
identification of patients who require dose adjustments for the prevention of adverse effects or lack of 
efficacy. The FDA has approved inclusion of pharmacogenetic data in the labelling of drugs like  
warfarin [128] and irinotecan [129] mainly for safety concerns. 
Pharmacogenomic data could also be utilized by the pharmaceutical industries as a part of drug 
development [130]. 
However a genetic or genome profile alone is not the only factor influencing a drug response for  
a disease: other factors such as age, gender, body mass, potential drug-drug interaction need to  
be considered. 
PharmGKB [131] is the leading pharmacogenetics and pharmacogenomics knowledge base 
(available online: http://www.pharmgkb.org) for annotation, integration, and aggregation of 
pharmacogenetic/pharmacogenomic knowledge through relationships with other resources, such as  
the University of California Santa Cruz (CA, USA) Genome Browser [132], Drugbank [133] and 
Biopax [134]. 
To obtain the above-indicated results, pharmacogenomic research strategies need to be accurately 
and rigorously conducted. Several commercial techniques are currently available and researchers may 
choose the most appropriate platform to use in their projects. Among them, the DNA microarray  
(also referred to as gene or genome chip, DNA chip or biochip) represents the most utilized technique. 
Although there have been numerous clinical studies and molecular genetics research in this area, we 
are still far from the possibility of extensive use of pharmacogenomics in clinical practice, primarily 
because the clear-cut demonstration that genotype-based dosing could definitely improve clinical 
outcomes is still lacking. In addition it is noteworthy that several barriers exist: economic, educational 
and legal. The evidence that the cost of pharmacogenomics test could be justified by clinical outcome 
is lacking. Medical students and practicing physicians must be educated and trained to use 
pharmacogenetic tests and properly interpret their clinical relevance [135,136]. 
Moreover, the need for complex data analysis and bioinformatics represents an additional obstacle 
to the expansion of “genomic medicine” [137]. Therefore, further studies are necessary to obtain more 
simple algorithms and statistical methods to discover genes variants or target genes influencing  
drug therapies. 
However, at the moment, only few “omics” research approaches have been undertaken in renal 
transplant medicine and, mostly, they have not been translated in “day to day” clinical practice. 
Int. J. Mol. Sci. 2015, 16 4292 
 
 
Among them, the Dutch Pharmacogenetics Working Group and Pharmacogenomics Knowledge 
Base have recently published dose recommendations based on TPMT genotype [138]. Additionally, as 
previously mentioned, the Clinical Pharmacogenetics Implementation Consortium has published 
guidelines on the use of TPMT genotyping in clinical practice [122]. 
Interstingly, also, the DeKAF study, a pharmacogenomic analysis of 945 Kidney transplant  
recipients has shown that a number of SNPs in several genes were associated with early CsA-related 
nephrotoxicity [139]. 
4. Research on New Therapeutic Targets for Immunosuppression 
In the last decade, nephrology researchers have started to employ “omics” techniques to select new 
potential therapeutic targets for immunosuppression. 
In 2003 Sarwal et al. [140] demonstrated that a systematic analysis of gene-expression patterns was 
able to reveal a specific biology and pathogenesis fingerprints of renal allograft rejection. Biopsy 
samples from patients with acute rejection that are indistinguishable on conventional histologic 
analysis demonstrated extensive differences in gene expression, which are associated with differences 
in immunologic and cellular features and clinical course. The presence of dense clusters of B cells  
in a biopsy sample was strongly associated with severe graft rejection, suggesting a pivotal role of  
infiltrating B cells in acute rejection. Based on these results, authors speculated that in patients who 
have such an infiltration, early treatment with a monoclonal antibody against CD20 (rituximab) could 
be beneficial. 
Subsequently, a similar methodological approach has been undertaken to recognize biological 
elements specifically involved in the development of immunological tolerance in renal transplantation. 
Some transplant recipients, in fact, display a stable graft function without immunosuppression  
namely “operational tolerance” [141,142]. The identification of “biomarkers of tolerance” could  
enable physicians to recognize patients in which immune therapy could be minimized or interrupted.  
The “tolerogenic” signature currently suggested, contains genes encoding for protein implicated in 
apoptosis, immune quiescence and T cell responses [141]. 
More recently Newell et al. [143], through microarray technology and functional analysis found 
that tolerant patients exhibited increased numbers of total and naive B cells and had enhanced 
expression of B cell differentiation and activation genes compared with subjects receiving 
immunosuppression. In particular they found three genes (IGKV4-1, IGLLA, and IGKV1D-13) that 
predicted tolerance with 100% accuracy. These genes are all expressed during the differentiation of  
B cells from pre- to mature B cells or during B cell activation-induced transition. They suggest that 
transitioning or maturing B cells are involved in tolerance induction and/or maintenance. 
However, additional studies are required to assess the clinical utility of the above-identified 
biological/cellular factors. 
Recently, our group, utilizing a high-throughput research strategy combined with classical 
bimolecular methodologies, revealed that neutral endopeptidase (NEP), an enzyme that catalyzes the 
degradation of a number of endogenous vasodilator peptides, such as angiotensin-II, was significantly 
up-regulated in renal transplant recipients after conversion from AZA to MPA. Immunohistochemical 
analysis confirmed results obtained by microarray and revealed that glomerular NEP was inversely 
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correlated with glomerulosclerosis and proteinuria, while tubular NEP was inversely associated with 
interstitial fibrosis. These results suggest that an MPA-induced up-regulation of NEP could decrease 
proteinuria and delay the progression of chronic renal damage in renal transplant recipients [144]. 
Furthermore, a combined strategy between classical biomolecular strategies and high-throughput 
technologies was able to identify, for the first time, that karyopherins, adaptor proteins that recognize 
the first discovered or classical NLS, may have a pivotal role in the development of delay  
graft function (DGF), and that these molecules may be new valuable therapeutic targets. In fact, in the last 
years, several drugs have been studied as inhibitors of karyopherin trafficking (e.g., importazole, 
Ivermectin) [145–148]. 
Also, several studies employing microarray methodologies have been undertaken to select potential 
pharmacological targets useful to minimize the onset of acute rejection. 
Kainz et al. [149], performing a complex genome-wide analysis using nucleic materials isolated 
from graft tissues obtained before and one-year post-transplantation, identified 52 genes able to 
accurately discriminate patients with excellent versus poor renal function. Up-regulated genes in 
patients with reduced graft function were involved in immunity and defense, signal transduction and 
response to oxidative stress, while down-regulated genes were mainly involved in metabolism, ion 
binding and transport. 
Finally, in a recent paper Saint-Mezard et al. [150], through a comparative analysis among three 
different microarray datasets (GSE343, GSE9493 and GSE1563), identified a specific and early 
diagnostic “acute rejection transcript set” (including 70 genes). 
5. Conclusions 
The correct administration of immunosuppressive therapy has a significant impact in graft and 
patients’ survival. Several in vivo and in vitro studies underline that dosage has an important role in 
minimizing chronic graft damage, but unfortunately, except for the evaluation of trough drug levels,  
no clinically useful tools are currently available to correctly manage immunosuppressive therapy. 
For this purpose, we believe that “omics” techniques represent powerful methods that could be 
routinely employed in the future to aid clinicians in the personalized treatment of patients to avoid 
severe toxicities/adverse effects and increase therapeutic potential (Figure 3). 
We are, however, still far from a realistic clinical employment of these strategies in nephrology and 
organ transplant medicine, and it seems reasonable that different professionals (physicians, scientists) 
should work together to rapidly overcome the scientific, economic, educational and legal barriers [151] 
that still exist before personalized medicine is achieved. 
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Figure 3. Prospective employment of pharmacogenetics and pharmacogenomics  
research strategies. 
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